final lecture 6

Question 1

anticoagulants

Answer 1

prevent clot formation

Question 2

antiplatelet drugs

Answer 2

interfere with platelet activity

Question 3

thrombolyte agents

Answer 3

dissolve existing thrombi

Question 4

heparin brand

Answer 4

UFH

Question 5

enoxaparin brand

Answer 5

lovenox

Question 6

dalteparin brand

Answer 6

fragmin

Question 7

fondaparinux brand

Answer 7

arixtra

Question 8

warfarin brand

Answer 8

coumadin

Question 9

dabigatran brand

Answer 9

pradaxa

Question 10

apixaban brand

Answer 10

eliquis

Question 11

rivaroxaban brand

Answer 11

xarelto

Question 12

SCORE IT

Answer 12

surgery
cancer/CV
obesity
respiratory failure
elderly
infection/inflammation/ICU
trauma/thromboembolism

Question 13

inferior vena cava (IVC) or greenfield filter

Answer 13

prevents PE but does not prevent DVT

Question 14

UFH prophylaxis

Answer 14

5000 units SQ Q8H

Question 15

enoxaparin (LMWH) prophylaxis

Answer 15

30 mg SQ Q12H (hip/knee)
40mg SQ QD
CrCL<30: 30mg QD

Question 16

Dalteparin (LMWH) prophylaxis

Answer 16

5000 units SQ QD- high risk

2500 units SQ QD- low/mod risk

Question 17

fondaparinux prophylaxis

Answer 17

2.5 mg QD

CI if <50kg

Question 18

rivaroxaban prophylaxis

Answer 18

10mg PO

Question 19

apixaban prophylaxis

Answer 19

2.5mg PO BID 12-24 before

Question 20

CHADS2 score

Answer 20

CHF, HTN, age >75, DM Stroke or TIA to determine stroke prophylaxis in afib